Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06338683
PHASE3

Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer

Sponsor: Qinghai Red Cross Hospital

View on ClinicalTrials.gov

Summary

This study aims to assess the impact of adding olanzapine to nutritional advice and standard anti-tumor therapy on the survival and safety of patients with locally advanced, unresectable or metastatic gastric cancer, esophageal cancer, hepato-pancreaticobiliary cancer, and lung cancer. Researchers seek to determine whether olanzapine can improve progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in advanced cancer patients who received standard anti-tumor therapy, and investigate the relationship between olanzapine-induced weight changes and patient survival.

Official title: Survival With the Addition of Olanzapine to Anticancer Therapy in Patients With Locally Advanced, Unresectable or Metastatic Gastric, Esophageal, Hepatopancreaticobiliary and Lung Cancer: a Randomized Clinical Trial

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

230

Start Date

2024-03-20

Completion Date

2028-03-20

Last Updated

2024-03-29

Healthy Volunteers

Yes

Interventions

DRUG

Olanzapine 2.5 MG

Oral olanzapine 2.5 mg once daily at bedtime until disease progression

DRUG

Standard anti-tumor treatment

Clinicians choose the appropriate standard antitumor drug therapy based on the patient's specific situation

DIETARY_SUPPLEMENT

Nutritional advice

All patients enrolled in the study were required to undergo a nutritional assessment and were provided with nutritional advice based on their condition

Locations (1)

Qinghai Red Cross Hospital

Xining, Qinghai, China